Basilea

BASILEA NEWSROOM (4 press releases)

Advanced Filtering & Sorting Options:

Archive by Year: All 2025 2024 2023 2022 2018 2017 2014 2013 2012

Basilea Launches FORWARD‑IM Phase 3 Trial of Fosmanogepix in Invasive Mold Infections

PRESS RELEASE -- 30, July 2025

(IN BRIEF) Basilea Pharmaceutica has initiated FORWARD‑IM, a global Phase 3 trial evaluating fosmanogepix in adults with invasive mold infections. Building on positive Phase 1 and Phase 2 results—and following the FAST‑IC Phase 3 candidemia trial—this open‑label study will randomize about 160 patients to … Read the full press release

BARDA Invests Additional USD 39 Million to Accelerate Phase 3 Trials of Basilea’s Fosmanogepix and BAL2062

PRESS RELEASE -- 8, July 2025

(IN BRIEF) Basilea Pharmaceutica has secured an extra USD 39 million from BARDA under its Other Transaction Agreement, bringing potential non-dilutive funding to USD 268 million over 12 years. This new tranche will finance the ongoing phase 3 trial of … Read the full press release

Basilea Achieves Second Consecutive Sales Milestone for Cresemba in Japan Through Asahi Kasei Pharma Partnership

PRESS RELEASE -- 24, April 2025

(IN BRIEF) Basilea Pharmaceutica has received a CHF 1.7 million milestone payment from its partner Asahi Kasei Pharma following continued strong sales of Cresemba® in Japan—marking the second consecutive quarterly milestone. Cresemba, now marketed in over 70 countries, achieved USD … Read the full press release

Basilea’s Cresemba Achieves Key Sales Milestone in Japan and Strong Global Growth

PRESS RELEASE -- 5, February 2025

(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 million sales milestone payment from its partner Asahi Kasei Pharma. This achievement, reached in just the second year of … Read the full press release